Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer

Mariacarmela Santarpia, Nuno Gil, Rafael Rosell

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The use of molecularly targeted agents has dramatically improved the prognosis of defined subsets of patients with non-small-cell lung cancer harboring somatically activated oncogenes, such as mutant EGFR or rearranged ALK. However, after initial marked responses to EGFR or ALK tyrosine kinase inhibitors (TKIs), almost all patients inevitably progress due to development of acquired resistance. Multiple molecular mechanisms of resistance have been identified; the best characterized are secondary mutations in the tyrosine kinase domain of the oncogene, such as T790M in EGFR and L1196M in ALK, which prevent target inhibition by the corresponding TKI. Other mechanisms include copy number gain of the ALK fusion gene and the activation of bypass signaling pathways that can maintain downstream proliferation and survival signals despite inhibition of the original drug target. Here, the authors provide an overview of the known mechanisms of resistance to TKIs and outline the therapeutic strategies, including new investigational agents and targeted therapies combinations, that have been developed to overcome resistance.

Original languageEnglish
Pages (from-to)461-477
Number of pages17
JournalExpert Review of Clinical Pharmacology
Volume8
Issue number4
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Oncogenes
Transcriptional Activation
Mutation
Survival
Therapeutics
Pharmaceutical Preparations

Keywords

  • ALK
  • EGFR
  • non-small-cell lung cancer
  • TKI resistance
  • TKIs

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. / Santarpia, Mariacarmela; Gil, Nuno; Rosell, Rafael.

In: Expert Review of Clinical Pharmacology, Vol. 8, No. 4, 01.07.2015, p. 461-477.

Research output: Contribution to journalArticle

Santarpia, Mariacarmela ; Gil, Nuno ; Rosell, Rafael. / Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. In: Expert Review of Clinical Pharmacology. 2015 ; Vol. 8, No. 4. pp. 461-477.
@article{56fef0e48d554e2a9d3475844725821e,
title = "Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer",
abstract = "The use of molecularly targeted agents has dramatically improved the prognosis of defined subsets of patients with non-small-cell lung cancer harboring somatically activated oncogenes, such as mutant EGFR or rearranged ALK. However, after initial marked responses to EGFR or ALK tyrosine kinase inhibitors (TKIs), almost all patients inevitably progress due to development of acquired resistance. Multiple molecular mechanisms of resistance have been identified; the best characterized are secondary mutations in the tyrosine kinase domain of the oncogene, such as T790M in EGFR and L1196M in ALK, which prevent target inhibition by the corresponding TKI. Other mechanisms include copy number gain of the ALK fusion gene and the activation of bypass signaling pathways that can maintain downstream proliferation and survival signals despite inhibition of the original drug target. Here, the authors provide an overview of the known mechanisms of resistance to TKIs and outline the therapeutic strategies, including new investigational agents and targeted therapies combinations, that have been developed to overcome resistance.",
keywords = "ALK, EGFR, non-small-cell lung cancer, TKI resistance, TKIs",
author = "Mariacarmela Santarpia and Nuno Gil and Rafael Rosell",
year = "2015",
month = "7",
day = "1",
doi = "10.1586/17512433.2015.1055252",
language = "English",
volume = "8",
pages = "461--477",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "ROUTLEDGE JOURNALS, TAYLOR FRANCIS LTD",
number = "4",

}

TY - JOUR

T1 - Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer

AU - Santarpia, Mariacarmela

AU - Gil, Nuno

AU - Rosell, Rafael

PY - 2015/7/1

Y1 - 2015/7/1

N2 - The use of molecularly targeted agents has dramatically improved the prognosis of defined subsets of patients with non-small-cell lung cancer harboring somatically activated oncogenes, such as mutant EGFR or rearranged ALK. However, after initial marked responses to EGFR or ALK tyrosine kinase inhibitors (TKIs), almost all patients inevitably progress due to development of acquired resistance. Multiple molecular mechanisms of resistance have been identified; the best characterized are secondary mutations in the tyrosine kinase domain of the oncogene, such as T790M in EGFR and L1196M in ALK, which prevent target inhibition by the corresponding TKI. Other mechanisms include copy number gain of the ALK fusion gene and the activation of bypass signaling pathways that can maintain downstream proliferation and survival signals despite inhibition of the original drug target. Here, the authors provide an overview of the known mechanisms of resistance to TKIs and outline the therapeutic strategies, including new investigational agents and targeted therapies combinations, that have been developed to overcome resistance.

AB - The use of molecularly targeted agents has dramatically improved the prognosis of defined subsets of patients with non-small-cell lung cancer harboring somatically activated oncogenes, such as mutant EGFR or rearranged ALK. However, after initial marked responses to EGFR or ALK tyrosine kinase inhibitors (TKIs), almost all patients inevitably progress due to development of acquired resistance. Multiple molecular mechanisms of resistance have been identified; the best characterized are secondary mutations in the tyrosine kinase domain of the oncogene, such as T790M in EGFR and L1196M in ALK, which prevent target inhibition by the corresponding TKI. Other mechanisms include copy number gain of the ALK fusion gene and the activation of bypass signaling pathways that can maintain downstream proliferation and survival signals despite inhibition of the original drug target. Here, the authors provide an overview of the known mechanisms of resistance to TKIs and outline the therapeutic strategies, including new investigational agents and targeted therapies combinations, that have been developed to overcome resistance.

KW - ALK

KW - EGFR

KW - non-small-cell lung cancer

KW - TKI resistance

KW - TKIs

UR - http://www.scopus.com/inward/record.url?scp=84933524565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933524565&partnerID=8YFLogxK

U2 - 10.1586/17512433.2015.1055252

DO - 10.1586/17512433.2015.1055252

M3 - Article

C2 - 26068305

AN - SCOPUS:84933524565

VL - 8

SP - 461

EP - 477

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 4

ER -